Supplementary Table S9. Head and neck cancer patient characteristics, median survival, and Multivariate Cox Regression Modeling.

Patient Characteristics (Head & Neck)		LOR	ALP	No Benzo	Overall	P-value
	N	171 (21.3)	86 (10.7)	546 (68.0)	803 (100%)	
Sex	Female	50 (29.2%)	31 (36.0%)	174 (31.9%)	255 (31.8%)	0.540
	Male	121 (70.8%)	55 (64.0%)	372 (68.1%)	548 (68.2%)	
Grade (Clinical)	I	13 (9.1%)	8 (10.1%)	60 (11.2%)	81 (10.7%)	0.559
	II	67 (46.9%)	32 (40.5%)	205 (38.3%)	304 (40.2%)	
	III	29 (20.3%)	19 (24.1%)	150 (28.0%)	198 (26.2%)	
	IV	3 (2.1%)	1 (1.3%)	5 (0.9%)	9 (1.2%)	
	Not Reported	31 (21.7%)	19 (24.1%)	115 (21.5%)	165 (21.8%)	
Grade (Pathological)	I	12 (8.5%)	7 (8.9%)	60 (11.2%)	79 (10.4%)	0.493
	II	61 (43.0%)	33 (41.8%)	204 (38.1%)	298 (39.4%)	
	III	29 (20.4%)	18 (22.8%)	151 (28.2%)	198 (26.2%)	
	IV	3 (2.1%)	1 (1.3%)	5 (0.9%)	9 (1.2%)	
	Not Reported	37 (26.1%)	20 (25.3%)	115 (21.5%)	172 (22.8%)	
Stage (Clinical)	0	3 (1.8%)	1 (1.2%)	8 (1.5%)	12 (1.5%)	0.027
	I	27 (15.8%)	13 (15.1%)	64 (11.7%)	104 (13.0%)	
	II	27 (15.8%)	4 (4.7%)	63 (11.5%)	94 (11.7%)	
	III	26 (15.2%)	11 (12.8%)	53 (9.7%)	90 (11.2%)	
	IV	48 (28.1%)	23 (26.7%)	192 (35.2%)	263 (32.8%)	
	Not Reported	40 (23.4%)	34 (39.5%)	166 (30.4%)	240 (29.9%)	
Stage (Pathological)	0	1 (0.6%)	1 (1.2%)	7 (1.3%)	9 (1.1%)	0.509
	I	7 (4.1%)	5 (5.9%)	49 (9.0%)	61 (7.6%)	
	II	5 (2.9%)	1 (1.2%)	17 (3.1%)	23 (2.9%)	
	III	7 (4.1%)	2 (2.4%)	20 (3.7%)	29 (3.6%)	
	IV	21 (12.4%)	10 (11.8%)	82 (15.0%)	113 (14.1%)	
	Not Reported	129 (75.9%)	66 (77.6%)	371 (67.9%)	566 (70.7%)	
Overall Survival Indicator	Alive	53 (31.0%)	33 (38.4%)	212 (38.8%)	298 (37.1%)	0.175
	Dead	118 (69.0%)	53 (61.6%)	334 (61.2%)	505 (62.9%)	
Progression-Free Survival Indicator	No Progression	49 (28.7%)	32 (37.2%)	199 (36.4%)	280 (34.9%)	0.156
	Progression	122 (71.3%)	54 (62.8%)	347 (63.6%)	523 (65.1%)	

Overall Survival (OS)	Median Surv. (95% CI)	Sample: Head & Neck	Log Rank P-value
Total	55.2 (44.2, 68.0)	E=505 C=298 T=803	p= 0.012
ALP	51.3 (30.7, 90.6)	E=53 C=33 T=86	
LOR	35.0 (23.8, 56.5)	E=118 C=53 T=171	
No Benzo	63.7 (48.2, 79.1)	E=334 C=212 T=546	

Progression-Free Survival (PFS)	Median Surv. (95% CI)	Sample: Head & Neck	Log Rank P-value
Total	38.7 (30.6, 52.1)	E=523 C=280 T=803	p= 0.006
ALP	40.3 (23.7, 75.2)	E=54 C=32 T=86	
LOR	29.2 (18.0, 44.0)	E=122 C=49 T=171	
No Benzo	46.8 (32.0, 61.3)	E=347 C=199 T=546	

Overall Survival (OS)		
Predictors: Cohort, Sex, Clinical Grade, and Clinical Stage		
Cohort	**HR (95% CI)**	**P-value**
No Benzo	Ref.	<.0001
ALP	1.227 (0.907 – 1.660)	0.1845
LOR	1.629 (1.304 – 2.035)	<.0001
Progression-Free Survival (PFS)		
No Benzo	Ref.	<.0001
ALP	1.235 (0.917 – 1.662)	0.1647
LOR	1.635 (1.313 – 2.036)	<.0001

E= event, C= censored, T= Total